ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)

The goal of the study is to conduct a comparative randomized trial of electroconvulsive therapy (ECT) vs. ketamine for patients with treatment resistant depression (TRD) in a real world setting with patient reported outcomes as primary and secondary outcome measures.

Topic Treatment-Resistant Depression
Compound Ketamine
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

The Cleveland Clinic
This company doesn't have a full profile yet, it is linked to a clinical trial.

Patient-Centered Outcomes Research Institute
This company doesn't have a full profile yet, it is linked to a clinical trial.

Papers

Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
This open-label, randomized trial (n=403) compared the effectiveness of iv ketamine (35mg/70kg, 6x, 3w) and electroconvulsive therapy (ECT) in treating treatment-resistant major depression (TRD). The results showed that 55.4% of patients in the ketamine group and 41.2% in the ECT group responded to the treatment, indicating ketamine was noninferior to ECT. ECT was associated with a temporary decrease in memory recall, while ketamine was associated with dissociation. Both treatments had similar improvements in patient-reported quality of life, with ECT having musculoskeletal adverse effects.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.